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The Southampton norovirus (SV) capsid protein was expressed as VLPs by recombinant baculoviruses in insect cells and was used to
immunize mice for the production of monoclonal antibodies (mAbs). One mAb, CM54, showed broad cross-reactivity to genogroup I (GI)
noroviruses, but was not reactive to GII capsid proteins. Interestingly mAb CM54 reacted to a bovine norovirus capsid protein. Immunoblot
analysis indicated the binding site for CM54 was located in the shell domain between amino acid residues 102–225 of the SV capsid protein. The
epitope was mapped to high resolution using a peptide array and was located to the sequence LEDVRN at amino acid residues 162–167.
Alignment of norovirus capsid protein sequences confirmed the epitope sequence was common to particular groups of human and bovine
noroviruses. Modeling of the epitope onto the recombinant NV capsid protein revealed it was located to the inner surface of the shell domain.
© 2006 Elsevier Inc. All rights reserved.Keywords: Norovirus; Capsid; Monoclonal antibody; EpitopeIntroduction
Caliciviruses cause a variety of diseases in humans and
animals. On the basis of phylogenetic variation and genome
organization, members of the Caliciviridae have been divided
into four distinct genera; vesiviruses, lagoviruses, noroviruses
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doi:10.1016/j.virol.2006.07.034phylogenetic analyses, a fifth calicivirus genus has been
proposed for the bovine viruses Nebraska (NB) (Smiley et al.,
2002) and Newbury agent-1 (NA-1) (Oliver et al., 2006a).
Viruses in the genera Norovirus and Sapovirus are the causative
agents of non-bacterial gastroenteritis in man, cattle and swine
(Liu et al., 1999; Sugieda et al., 1998; Kapikian, 1994; Bridger
et al., 1984). The noroviruses have been subdivided into five
genogroups (Fankhauser et al., 2002): viruses in genogroups I,
II and IVare associated with humans; genogroup III noroviruses
are associated with bovines and genogroup V is represented by
the newly discovered mouse norovirus (MNV-1) (Karst et al.,
2003).
Norovirus research has been greatly hindered by the inability
to propagate noroviruses in cell culture and the low number of
viruses in clinical specimens. To date, studies on human
noroviruses have relied on clinical specimens and materials
obtained from infected volunteers. Noroviruses are highly
infectious and spread rapidly by person to person in closed and
semiclosed environments (Green et al., 2002; Marx et al., 1999)
or through the contamination of food and water (Khan et al.,
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al., 1989; Perz et al., 2000). Traditionally diagnosis of norovirus
infection has relied on the observation of virus particles by EM
(Caul and Appleton, 1982). However, a significant advance in
studying the noroviruses came with the discovery that
expression of the prototype Norwalk virus (NV) capsid protein
in insect cells, where it forms virus-like particles (VLPs) (Jiang
et al., 1992). Subsequently, capsid proteins from a number of
different noroviruses have been expressed in insect cells (Jiang
et al., 1995; Kobayashi et al., 2000b; Dingle et al., 1995; Deng
et al., 2003; Green et al., 1997) and all assemble to form VLPs
that are morphologically and antigenically indistinguishable
from native viruses (Green et al., 1993). The X-ray crystal-
lographic structure of the NV capsid protein has been resolved
to 3.2 Å and showed that the capsid consists of 90 dimers of a
single protein with a T=3 icosahedral symmetry. A single
capsid protein has two principal domains, the shell domain
(amino acid residues 1–225) and the protruding domain (P),
which is divided into two subdomains, P1 (amino acid residues
226–278 and 406–530) and P2 (amino acid residues 279–405),
with the P2 subdomain most protruding. It has been suggested
that the P2 subdomain is highly antigenic and probably
responsible for determinants of strain specificity (Prasad et al.,
1999). Norovirus VLPs are now an abundant and renewable
source of antigen and have been used to generate specific
antisera for use in antigen detection enzyme-linked immuno-
sorbent assays (Vipond et al., 2000; Graham et al., 1994; Karst
et al., 2003; Lewis et al., 1997; Honma et al., 1998; Deng et al.,
2003; Kobayashi et al., 2000a).
Monoclonal antibodies (mAbs) have been raised against
recombinant norovirus capsid proteins (Treanor et al., 1988;
Yoda et al., 2000, 2001; Herrmann et al., 1995; Hardy et al.,
1996). mAbs with different binding characteristics have been
reported and an epitope from one mAb (that binds the
recombinant NV capsid protein) has been located between
amino acid residues 457–530 in the P1 domain, common to
genogroup I noroviruses (Hardy et al., 1996; Hale et al., 2000).
In a similar study, Yoda et al. characterized an epitope in the
shell domain recognized by a genogroup cross-reactive mAb.
Recently, a cross-reactive epitope present in GIII and GII/3
noroviruses was reported (Oliver et al., 2006b).
The purpose of this work was to identify mAbs showing a
broad reactivity to noroviruses and to locate cross reactive
epitopes on the capsid protein.
Results
Expression of capsid proteins in insect cells
The capsid protein of a novel GI/5 norovirus (Babbacombe
isolate (Bab)), which shares 74.5% amino acid sequence
identity with the SV capsid protein, was cloned and expressed
as VLPs. The r-Bab capsid protein was expressed in insect cells
and a time course of expression indicated that r-Bab capsid
protein was detectable in infected cells from day 2 onwards. The
r-Bab capsid protein was present as a doublet at 52 and 59 kDa
and these proteins were exported to the cell culture supernatantfrom day 4 onwards (data not shown). r-Bab VLPs were
purified by density gradient centrifugation and gradient
fractions with a buoyant density of 1.34 g/ml contained VLPs
as visualized by EM.
Expression of capsid proteins in E. coli
To increase the probability of isolating a monoclonal
antibody reactive to a linear epitope, GST capsid fusion proteins
were generated from the capsid genes for GI, GII and GIII
noroviruses as described by Oliver et al. (2006b). Similarly a
series of overlapping SV capsid protein fragments were
expressed fused to GST in E. coli.
Antibodies to recombinant norovirus capsid proteins
Preliminary experiments screening hybridoma supernatants
indicated that a large proportion of the hybridoma clones were
producing antibodies to highly immunogenic baculovirus and
insect cell antigens. Large numbers of selected hybridomas
were found to secrete antibodies reactive with a 60-kDa
baculovirus protein which was presumed to be the viral
chitinase. This protein has a similar molecular weight to the
norovirus capsid protein (data not shown) confusing interpreta-
tion of antibody reactivity by immunoblot analysis. These
findings indicated that purified VLP preparations were
contaminated with highly immunogenic baculovirus compo-
nents. To circumvent this problem, we sought to produce an
alternative source of norovirus capsid protein devoid of insect
cell and baculovirus antigens for screening hybridomas
secreting cross-reacting mAbs. For this purpose, the SV capsid
protein fused to GST was expressed in E. coli using the vector
pGex4T1. Analysis of bacterial cell cultures post-induction
indicated that the SV-GST fusion protein was expressed as
insoluble inclusion bodies. Purification of the SV-GST fusion
protein was achieved using “Bugbuster” (Novagen, UK) and the
yield of protein was estimated to be 750 μg/100 ml culture.
Mice were immunized with r-SV VLPs and hybridomas
were screened by direct ELISA to SV-GST fusion protein. The
selection of hybridomas based on their reactivity to SV-GST
expressed and purified from E. coli was performed both to
avoid the selection of mAbs reacting to baculovirus antigens
and to increase the probability of selecting mAbs to linear
epitopes. Hybridomas were cloned by terminal dilution and to
ensure reactivity to authentic epitopes on the SV capsid protein,
supernatants from the dilutions were tested in radioimmune
precipitation assays to SV capsid protein expressed by in vitro
transcription/translation. A single hybridoma (CM54) with the
required binding characteristics was selected for further study.
A cross-reacting genogroup-specific monoclonal antibody
mAb CM54 was isotyped as IgM using the Mouse Typer®
Sub-isotyping Kit (Bio-Rad, UK). To investigate the binding
characteristics of mAb CM54, it was screened by direct ELISA
for cross-reactivity to a panel of recombinant norovirus capsid
proteins representing genogroups I–III (SV, Bab, DSV, NV,
Fig. 2. Immunoblot of SV capsid proteins expressed in E. coli. Recombinant
fragments of Southampton virus (SV) capsid protein fused to GSTand expressed
in E. coli were separated by SDS-PAGE and transferred to a nitrocellulose
membrane which was reacted with hybridoma cell culture supernatant of mAb
CM54. Tracks SVF1, SVF4 and SVF5 are cellular fractions of E. coli expressing
fragments of the SV capsid protein post induction. mAb CM54 reacted with
fragments SVF1 (amino acid residues 1–225) and SVF5 (amino acid residues
102–225), however, showed no reactivity to SVF4 (amino acid residues 1–124).
The arrows indicate the estimated molecular weights for the two fusion proteins
SVF1 and SVF5 respectively.
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et al., 2003) and NA-2 (Oliver et al., 2006b). mAb CM54
reacted to GI norovirus capsid proteins (SV (GI/1), Bab (GI/5),
DSV (GI/3) and NV (GI/2)) and NA-2 capsid protein (GIII/2),
but was non-reactive to GII norovirus capsid proteins or JV
capsid protein (GIII/1). To confirm the pattern of cross-
reactivity, mAb CM54 was used to immunoprecipitate the SV
and Bab capsid proteins produced by in vitro transcription/
translation. mAb CM54 immunoprecipitated the 58-kDa SV
capsid protein and the 59-kDa Bab capsid protein (data not
shown). The binding characteristics of mAb CM54 were
investigated further by immunoblot (Fig. 1) against a panel of
GI recombinant capsid proteins representing the major genetic
clusters, the predominant Lordsdale GII/4 norovirus r-LV
(Ando et al., 2000) and GIII/2 norovirus r-NA-2.
mAb CM54 reacted by immunoblot to the GI norovirus
capsid proteins and GIII/2 norovirus NA-2 capsid protein, but
did not bind to the LV (GII/4) capsid protein, indicating that
mAb CM54 recognizes a continuous (linear) epitope common
to GI and GIII/2 norovirus capsid proteins.
mAb CM54 was used to probe the antigenic structure of the
SV capsid protein. A series of overlapping SV capsid protein
fragments (SVF1, SVF2 and SVF3) were expressed fused to
GST in E. coli. mAb CM54 reacted by immunoblot to SVF1
(amino acid residues 1–225) but not SVF2 or SVF3 (data not
shown). The cDNA for SVF1 was cloned as two overlapping
halves to produce plasmids expressing SV capsid protein
fragments 4 and 5 (SVF4 and SVF5 respectively). mAb CM54
reacted by immunoblot to SVF5 (amino acid residues 102–225)
(Fig. 2), but not SVF4 and showed no reactivity to expressed
GST. The pattern of reactivity towards the SV capsid protein
fragments showed that mAb CM54 recognized an epitope in the
shell domain of the GI norovirus capsid.
High-resolution mapping of the epitope recognized by mAb
CM54
To map at high-resolution the epitope recognized by mAb
CM54, a peptide array was designed for amino acids 102–225
of the SV capsid protein. The peptide array consisted of
dodecamers overlapped by three amino acids to resolve the
epitope to a minimum of six amino acid residues. mAb CM54Fig. 1. Immunoblot of recombinant norovirus capsid proteins. Purified capsid
proteins expressed in insect cells from recombinant baculoviruses were
separated by SDS-PAGE and transferred to a nitrocellulose membrane which
was reacted with the hybridoma cell culture supernatant of mAb CM54. Lanes
1–4 are from genogroup I noroviruses: Southampton virus (SV GI/1),
Babbacombe virus (Bab GI/5), Desert Shield virus (DSV GI/3) and Norwalk
virus (NV GI/1), lane 5 genogroup II Lordsdale virus (LV GII/4) and the final
lane, lane 6 genogroup III Newbury Agent-2 (NA-2 GIII/2). The arrow shows
the size of the recombinant SV capsid protein. mAb CM54 reacted with the GI
norovirus capsid proteins and GIII/2 capsid protein, however, showed no
reactivity to GII (LV) capsid protein.bound to six peptides, 9 to 11 and 19 to 21 that corresponded
to overlapping amino acid residues 132FTSSSL137 and
162LEDVRN167 in the SV capsid protein (Fig. 3A). The
reactivity of CM54 to the predominant epitope LEDVRN was
approximately 8-fold higher compared to the reactivity to
FTSSSL. The two CM54 epitopes had a close proximity to one
another in the capsid monomer as determined by molecular
modeling, suggesting that the CM54 antibody recognized both
linear and a conformational epitope. The FTSSSL and
LEDVRN epitopes were located inside the norovirus capsid
shown by macromolecular models of the capsid protein for the
5-fold axis of symmetry (Figs. 3B and C).
Norovirus capsid protein sequences available from Genbank
were aligned to determine the distribution of this epitope within
the Norovirus genus. The predominant epitope LEDVRN was
conserved in GI, but not GII noroviruses (Fig. 4). Interestingly,
the “epitope” sequence was not conserved in the JV (GIII/1)
capsid protein, but conserved in the NA-2 (GIII/2) capsid
protein, confirming the ELISA and immunoblot results. The
FTSSSL component of the epitope showed little amino acid
conservation for this region of the GII and GIII norovirus capsid
proteins (data not shown).
Discussion
In this study, we used immunization with SVVLPs to produce
a hybridoma secreting a mAb (CM54) that recognized an epitope
common to GI and GIII/2 norovirus capsid proteins. mAb CM54
was selected based on its reactivity by direct ELISA with a
complete SV capsid-GST fusion protein to help facilitate the
Fig. 3. High-resolution mapping and localization of the mAb CM54 epitopes. (A) Immunoreactivity by ELISA of mAb CM54 with 39 peptides generated from 123
amino acids at the NH2 terminal of the SV capsid protein. A molecular model of the genogroup I norovirus Norwalk showing the location of the epitopes
(132FTSSSL137; orange space fill and 162LEDVRN167; purple space fill) in the capsid protein monomer that reacted with the mAb CM54. Green, NH2-terminal amino
acids; yellow, S domain; red, P1 domain; blue, P2 domain. The dotted lines highlight the reactivity by ELISA of the epitopes and their location in the capsid protein.
Molecular models of the five-fold axis of symmetry for the Norwalk virus viewed from the top (B) or side (C), showing the likely locations of the epitopes for CM54.
The epitopes (orange and purple) are located on the inside of the viral capsid.
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CM54 showed broad cross-reactivity by ELISA, immunoblot
and RIPA to GI capsid proteins, including Bab virus (a previously
uncharacterized GI/5 norovirus) and to NA-2 (GIII/2) capsid
protein. mAb CM54 did not appear to react by ELISA (data not
shown) with native virus, but this probably reflects the extremely
low levels of virus in some clinical specimens. Until such time as
it becomes possible to cultivate human and bovine noroviruses,
reactivity with native virus will depend on the chance collection
of a stool sample containing high titers of virus.
The reactivities of mAb CM54 suggested it recognized a
continuous (linear) epitope shared among the GI and GIII/2noroviruses. In a separate study, strain-specific and genogroup-
specific mAbs were obtained frommice immunized orally with a
single recombinant norovirus VLP or two norovirus VLPs from
different genogroups (Kitamoto et al., 2002) although to date the
epitopes recognized by these antibodies have not been reported.
The presence of cross-reactive epitopes shared between
human and bovine noroviruses has recently been reported by
Oliver et al. (2006b). To add to this finding, the epitope
recognized by mAb CM54 was mapped initially to low
resolution by immunoblot blot analysis to truncated forms of
the SV capsid protein expressed fused to GST in E. coli. mAb
CM54 bound to a short region of the shell domain. Others have
Fig. 4. Conservation of the predominant epitope LEDVRN with representatives
for genogroups I, II and III of the noroviruses. Alignment of Group I, Group II
and Group III norovirus partial capsid sequences between amino acids 151 and
180 of Southampton virus. The shaded box represents the epitope recognized by
monoclonal antibody CM54 and is located between amino acids 162 to 167.
Representative strains used for alignments are as follows: NV, Norwalk
(M87661); SeV Seto (Aichi) (AB031013); SV, Southampton (L07418); DSV,
Desert Shield (U04469); ChV, Chiba (AB042808); Bab, Babbacombe
(AM263418); HwV, Hawaii (U07611); Girl, Girlington (AJ277606); Melks,
Melksham (X81879); MxV, Mexico (U22498); RBH, RBH (AJ277617); LV,
Lordsdale (X86557); Leeds (AJ277608); JV, Jena (AJ011099); NA-2, Newbury
Agent 2 (AF097917).
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the P1 domain (amino acid residues 457–530) (Hale et al.,
2000). mAb CM54 had reactivity to two regions of the SV
capsid protein; a major epitope at amino acid residues
162LEDVRN167 and a minor reactive epitope at amino acid
residues 132FTSSSL137. The major epitope LEDVRN was
present in the GI and GIII/2, but not GII norovirus or GIII/1
capsid proteins. It is unlikely that the FTSSSL epitope
contributed to the cross-reactivity between the GIII/2 noro-
viruses because of the lack of amino acid conservation in this
region of the capsid proteins; however, in the three-dimensional
structure, these amino acid residues are in close proximity to the
conserved region (LEDVRN) and may contribute to the overall
affinity of mAb CM54 with its epitope.
The conservation of the LEDVRN epitope in the GI and
GIII/2 noroviruses was in accordance with reactivities observed
by ELISA and immunoblot to recombinant capsid proteins.
Sequence alignments suggested that in the LV (GII/4), HwV
(GII/1), Girl (GII/1) and Melks (GII/2) capsid proteins, an
amino acid substitution from glutamate (E) to proline (P) was
sufficient to prevent antibody binding by altering the overall
conformation of the epitope. In addition to the glutamate to
proline substitution, for MxV and RBH (GII/3) capsid proteins,
the leucine (L) residue has been substituted for methionine (M).
Sequence alignments with GIII norovirus capsid proteins
indicated that the epitope LEDVRN was not conserved in the
JV (GIII/1) capsid protein, but conserved in the NA-2 (GIII/2)
capsid protein in accordance with reactivities observed by
ELISA and immunoblot. JV-like (GIII/1) bovine noroviruses
have been detected in the stools of calves in Michigan and
Wisconsin. Alignment of partial capsid protein sequencesillustrated the epitope is not conserved in the JV-like bovine
noroviruses and is replaced by the sequence LADVRN (Wise et
al., 2004). The single amino acid change from a glutamate (E)
residue to an alanine (A) residue is likely to inhibit antibody
binding. However, in NA-2-like sequences, the epitope
recognized by mAb CM54 (LEDVRN) is conserved. Chakra-
varty et al. performed evolutionary trace analyses of noroviruses
and demonstrated the presence of absolutely conserved residues
(ACRs) and class-specific residues (conserved within evolu-
tionary classes). Interestingly, D*RN residues at amino acid
positions 164–167 are ACRs, while the glutamate (E) residue at
amino acid position 163 is a class-specific residue in GI
noroviruses (Chakravarty et al., 2005).
It is possible that mAb CM54 requires only the pentapeptide
sequence EDVRN for recognition. Analysis of 103 separate
protein sequences revealed, for most linear epitopes, five amino
acid residues were essential to antibody binding (Geysen et al.,
1988). Modeling of the amino acid sequence LEDVRN onto the
predicted r-NV capsid protein structure revealed that this epitope
is present on the interior surface of the virion in the S domain.
In 2005, Widdowson et al. investigated the possibility that
exposure to bovine noroviruses might result in infection in
humans. Human sera were tested for reactivity by ELISA,
against recombinant expressed bovine norovirus capsid protein
and a significant level of reactivity was found in 22% of test sera.
Reactivity of IgG antibodies was detected with both r-BoV and
r-NV (Widdowson et al., 2005). However, we have identified
and characterized an epitope in the S domain of the capsid
protein that is common to both GI and GIII/2 noroviruses.
Antibodies to this epitope are cross-reactive between GI and
GIII/2 by ELISA. The existence of cross-reactive epitopes
between different noroviruses is therefore a factor that needs to
be considered in any serological survey of human sera for
antibodies to bovine norovirus. This also highlights a require-
ment for an assay that can distinguish antibodies to different
noroviruses in polyclonal serum, in order to gain evidence of
any potential transmission of these viruses between host species.
This could be achieved by developing a panel of well-
characterized genogroup-specific mAbs, for use in competitive
ELISA to detect genogroup-specific antibodies in the test sera.
Characterization of antigenic sequences on the norovirus
capsid protein will make it possible to synthesize relevant
antigenic peptides. These could be used for the immunization of
laboratory animals and production of mAbs and/or polyclonal
antisera, for the development of improved diagnostic assays.
The availability of specific antibodies with defined binding
properties also provides useful tools for studying these
recalcitrant viruses.
Materials and methods
Noroviruses and VLPs
Norwalk virus (NV GI/1), Southampton virus (SV GI/2) and
Desert Shield virus (DSV GI/3) have been described previously
(Kapikian et al., 1972; Lambden et al., 1993; Lew et al., 1994).
NV was isolated from an adult during an outbreak of non-
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DSV was from military personnel during operation desert shield
(1990) in Saudi Arabia. SV was obtained in 1991 from a child
during a family outbreak of gastroenteritis in Southampton, UK.
Babbacombe virus (Bab) was obtained from a single diarrheic
stool specimen collected from an outbreak of gastroenteritis in a
hotel in Babbacombe, Devon, UK, in 1996. Sequence analyses
assigned Babbacombe virus to a GI/5 genotype according to the
recently published classification scheme (Zheng et al., 2006).
VLPs for genogroup I noroviruses were available for NV, SVand
DSV (Jiang et al., 1992; Pelosi et al., 1999) (Dr. Kim Green,
NIAH, personal communication), however, a new recombinant
baculovirus was constructed to express the Bab capsid. The
subgenomic region (ORF2-ORF3 and 3′ terminus) of Bab/96/
UK norovirus was cloned and sequenced as previously
described (Lambden et al., 1993). A polymerase chain reaction
(PCR) fragment carrying ORF 2, 3 and 3′ UTR of Bab/96/UK
norovirus was cloned into pSP73 using primer pair DORF-2
(5′-TAGTACATACTGGATCCAGC1ATGATGATGGC-
GTCTA16-3′) and PstI(T)203UTR (5′-TAGTACATACTCTGC-
AGAGC2375TTTTTTTTTTTTTTTTTTTTGGCATCAATTGT-
CCAAATCAA2334-3′) to generate the plasmid pSP73/Bab/96/
UK. The sequences in bold in primer DORF-2 indicates a BamHI
site and in primer PstI(T)203UTR indicates a PstI site to facilitate
subcloning. The 2386-bp fragmentwas released frompSP73/Bab/
96/UK by digestion using BamHI and PstI, purified and
subcloned into pFastBacI to generate the plasmid Bab/96/
UKpFastBacI. Transformants were screened by PCR using
primers D14 (5′-701TGCCCAATATACCCTTGC718-3′) and
D11 (5′-1588CACAGGCTTTAATTGATAGAA1567-3′), to con-
firm the presence of the insert. Recombinants carrying the correct
insert were used to generate recombinant baculoviruses by co-
transfection of insect cells.
Insect cell culture and the expression and purification of r-
Bab VLPs was performed as previously described. VLPs were
purified on cesium chloride gradients and analyzed by SDS-
PAGE (Pelosi et al., 1999).
Expression of complete SV capsid protein in E. coli
A PCR fragment carrying ORF 2 of SV was amplified from
pSP73/SV, a recombinant carrying the subgenomic region of the
SV genome (nt 5355–6995) using primer pair SV F (5′-GAC-
GACGGATCC5354ATGATGATGGCGTCTAAGGAC5374-3′)
and SV R (5′-GACGACGAATTC6995TTATATACGGCGCAC-
TCCAAG6975-3′). The sequence in bold in primer SV F indicates
a BamHI site and in SV R indicates an EcoRI site to facilitate
subsequent cloning into pGex-4T1. The purified fragment was
ligated into BamHI/EcoRI digested, dephosphorylated pGex-4T1
vector to generate the plasmid pGex-4T1/SV capsid. Transfor-
mants were screened by PCR using primers SV F and SV R and
recombinants carrying the correct insert were used for expression
studies. Expression of pGex-4T1/SV capsid was performed in
accordance with the manufacturer's protocol (Amersham Bios-
ciences, UK) and resulted in the formation of inclusion bodies
which were purified using “Bugbuster” (Novagen) according to
the manufacturer's instructions.Expression of SV capsid protein fragments
A series of overlapping SV capsid protein fragments were
generated from the recombinant plasmid pSP73/SV. PCR
fragments were obtained using forward primers containing the
restriction site BamHI and reverse primers containing the
restriction site SalI or EcoRI as indicated in bold (Table 1).
PCR products were amplified from pSP73/SV and digested
with appropriate enzymes prior to ligation into appropriately
digested, dephosphorylated pGex-4T1 vector to generate the
plasmids pGex-SVF1, pGex-SVF2, pGex-SVF3, pGex-SVF4
and pGex-SVF5. Colonies were screened by PCR using the
primers used to generate the fragments and transformants
carrying the correct insert were used for expression studies.
Protein expression was performed as outlined above.
Production of mAbs
Production of monoclonal antibodies against r-SV capsid
protein was performed as previously described (Oliver et al.,
2006b).
SDS-PAGE
SDS-PAGE was performed on protein samples using the
discontinuous buffer system method of Laemmli with 12.5%
acrylamide gels (acrylamide/bisacrylamide, 38.5:1 [wt/wt]
(Laemmli, 1970).
Immunodetection of proteins
Proteins separated by SDS-PAGE were electroblotted to
nitrocellulose sheets in transfer buffer (Tris–HCl 25 mM;
glycine 192 mM; SDS 0.1% (w/v); methanol 20% (v/v)) using a
Trans-Blot SD semidry blotter (Bio-Rad Laboratories Ltd.,
Hemel Hempstead, UK). After transfer of the proteins, the
nitrocellulose membrane was washed in TTBS/5% milk
(Marvel) blocking solution (TBS (NaCl 0.5 M; Tris–HCl
20 mM; pH 7.5) + Tween-20 0.05% (v/v) at 37 °C. The
blocking solution was discarded and the nitrocellulose was
rinsed twice with TTBS and once with TBS. mAb diluted 1/20
in 10% normal goat serum/TTBS was added to the nitrocellu-
lose strips or sheets for 16 h. After washing in TTBS,
membranes were treated with the secondary antibody (goat
anti-mouse IgM alkaline phosphatase conjugate, Sigma).
Alkaline phosphatase antibody conjugates were detected using
a BCIP/NBT (bromo-chloro-indolyl-phosphate/nitroblue tetra-
zolium salt) redox chromogenic reaction catalyzed by alkaline
phosphatase in a carbonate buffer (NaHCO3 0.1 mM; MgCl2
1.0 mM; pH 9.8).
Radioimmune precipitation assays (RIPA)
Full-length SV and Bab capsid genes cloned into pRSETA
(Invitrogen, UK) was used as template for in vitro transcription
and translation using a T7 RNA polymerase coupled reticulo-
cyte lysate system (TNT; Promega, Southampton, UK) in
Table 1
Primers used for the production of SV capsid fragments
Clone Fragment Primer pair Sequence of oligonucleotides
pGex-SV F1 SVF1 SV F1F GACTTAGGATCC
5354ATGATGATGGCGTCTAAGGAC5374
SV F1R ACGTGAGTCGAC
6029TTATATAGTAGGTGGGACAA6010
pGex-SV F2 SVF2 SV F2F GACTTAGGATCC
5972GTGCTCACGGCTCCTAGT5989
SV F2R ACGTGAGTCGAC
6644TTACACAAGAGCCTCACCAAATC6622
pGex-SV F3 SVF3 SV F3F GACTTAGGATCC
6593GCTAATCTGGCCCCCCCAGTA6613
SV F3R ACGTGAGAATTC
6995TTATATACGGCGCACTCCAAG6975
pGex-SV F4 SVF4 SV F1F GACTTAGGATCC
5354ATGATGATGGCGTCTAAGGAC5374
SV F4R ACGTGAGTCGAC
5693TTAAAGAAGAATCCTAACTCT5673
pGex-SV F5 SVF5 SV F5F GACTTAGGATCC
5657GGCTGGGTTGGAAATATG5674
SV F1R ACGTGAGTCGAC
6029TTATATAGTAGGTGGGACAA6010
Nucleotides in bold indicate restriction sites used for cloning.
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products from the TNT system (6 μl) were incubated with 2 μl
of undiluted antisera or 5 μl mAb in 600 μl of RIPA buffer
(10 mM Tris–HCl [pH7.5] 1 mM EDTA, 0.15 mM NaCl, 0.1%
SDS, 0.5% Empigen BB [N-dodecyl-N,N-dimethylglycine],
0.1 mM phenylmethylsulphonyl fluoride). After incubation at
37 °C for 1 h, goat anti-mouse immunoglobulin M attached to
beaded agarose (Sigma, UK) was added to adsorb immune
complexes. The beads were washed three times in RIPA buffer
and once in phosphate-buffered saline before solubilization of
immune complexes in sample dissociating buffer and separation
by SDS-PAGE. Gels were stained and prepared for autoradio-
graphy by treatment with 1 M sodium salicylate–50% methanol
for 30 min at room temperature; they were then dried under
vacuum and exposed to Kodak XAR-5 film at −70 °C.
Direct ELISA
Polyvinyl plates (INC Labs) were coated by incubation
overnight at 4 °C with 2 μg/ml recombinant capsid protein
(VLPs or GST fusion protein) in 15 mM Na2 CO3, 35 mM Na
HCO3, pH 9.6/0.02% NaN3. The wells were washed with PBS/
0.05% Tween 20 (PBST) and blocked with PBS/5% (w/v) skim
milk (Marvel) for 30 min at 37 °C. Hybridoma supernatants
were screened at a 1:5 dilution in PBS/1% (w/v) skim milk and
incubated for 1.5 h at 37 °C. After the plates were washed with
PBST, 100 μl of a 1:3000 dilution of goat anti-mouse polyvalent
horse radish peroxidase conjugate (Sigma, UK) diluted in PBS/
1% skim milk was added and the plates were incubated for 1.5 h
at 37 °C. Plates were washed with PBST before development
with 100 μl substrate (0.1% sodium acetate pH 6.0, 0.1% tetra
methyl benzidine, 0.01% H2O2) at room temperature. The
reaction was stopped with the addition of 50 μl 2 M H2SO4 after
12 min. The absorbance at A450 of each well was read using an
Anthos HTII plate reader (Anthos Labtec, Salzburg, Austria).
Epitope analysis
A peptide array consisting of 39 overlapping dodecamers
offset by three amino acids was designed and synthesized by
Mimotopes, UK. The peptides spanned amino acids 102–225 of
the NH2 terminal region of the SV capsid protein. The peptide
array was synthesized on a series of solid phase ‘pegs’ in a12×8, 96-well ELISA tray format. Epitope analysis was
performed by a simple ELISA assay in accordance with the
manufacturer's protocol. Briefly the pegs were submerged in a
96-well polyvinyl plate containing 200 μl precoat buffer per
well (2% (w/v) BSA, 0.1% (v/v) Tween 20, 0.1% (w/v) Sodium
Azide in 0.01 M PBS pH 7.2) for 1 h at room temperature. All
subsequent incubations were performed by submersion in a 96-
well tray. The pegs were incubated overnight at 4 °C with 200 μl
per well 1/5 dilution in precoat buffer of hybridoma supernatant
CM54. The pegs were washed four times for 10 min in 0.01 M
PBS and submerged in 200 μl per well goat anti-mouse
horseradish peroxidase conjugate, diluted in conjugate diluent
(1% (v/v) Normal goat serum, 0.1% (v/v) Tween 20, 0.1% (w/v)
sodium caseinate in 0.01 M PBS pH 7.2) at a working
concentration of 0.25 μg/ml for 1 h at room temperature. The
pegs were washed four times as previously stated. ABTS
(0.05% (w/v)) was dissolved in 20 ml substrate buffer
(0.1MNa2HPO4, 0.08 M citric acid pH 4.0, 0.01% (w/v)
H2O2) and the pegs were incubated for 45 min with 200 μl
substrate per well and the absorbance at A405 of each well was
read using an Anthos HTII plate reader.
Molecular modeling
X-ray crystallography coordinates of the Norwalk virus
capsid protein (PDB accession number 1ihm) for the quaternary
structure of the five-fold axis of symmetry were obtained from
the Macromolecular Structure Database (http://www.pqs.ebi.ac.
uk/). To show the location of the Southampton virus epitope
sequences (132FTSSSL137 and 162LEDVRN167) in the capsid
protein monomer and the five-fold axis of symmetry of the
Norwalk virus, image files were generated using the software
program VMD 1.8.4 (Humphrey et al., 1996). Pov-ray for
Windows was used to generate ray traced images for all of the
structures. The domains of the Norwalk virus were amino acids
1 to 49 for the NH2-terminal domain, 50 to 225 for the S domain,
226 to 278 and 406 to 530 for the P1 domain, and 279 to 405 for
the P2 domain as previously reported (Prasad et al., 1999).
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